Clinical Management in Diagnosis and Treatment of the Iron Deficiency Anemia in Adults: Systemic Review by Alharbi, Fahad Obaid et al.
Journal of Health, Medicine and Nursing                                                                                                                                          www.iiste.org 
ISSN 2422-8419     An International Peer-reviewed Journal 
Vol.46, 2018 
 
1 
Clinical Management in Diagnosis and Treatment of the Iron 
Deficiency Anemia in Adults: Systemic Review 
 
Dr. Fahad Obaid Alharbi1      Dr. Tameem Abdulaziz Alhomaid1      Dr. Hatim Saeed T Alshahrani2 
Dr. Ayedh Mubarak Ayedh Al Bishi3      Dr. Jamal Jeza Mohsen Alrashidi1      Dr. Mohammed Saleh Alhulayfi4 
Dr. Sulaiman Shulaywih Alharbi1 
1.Qassim University 
2.King Khalid University 
3.Albaha University 
4.Dammam Medical Complex) 
 
Abstract 
This study aimed at exploring with a systematic review the clinical management in diagnosis and treatment of 
the iron deficiency anemia in adults, as the iron deficiency is the most frequent cause of anemia worldwide. And 
it impairs quality of life, increases asthenia and can lead to clinical worsening of patients. In addition, iron 
deficiency has a complex mechanism whose pathologic pathway is recently becoming better understood. This 
review summarizes the current knowledge regarding diagnostic algorithms for iron deficiency anemia. The 
majority of aetiologies occur in the digestive tract, and justify morphological examination of the gut. First line 
investigations are upper gastrointestinal endoscopy and colonoscopy, and when negative, the small bowel should 
be explored; newer tools such as video capsule endoscopy have also been developed. The treatment of iron 
deficiency is aetiological if possible and iron supplementation whether in oral or in parenteral form. 
  
1.1 Introduction 
Disorders of iron metabolism are common human pathologic conditions. Iron deficiency, defined as low body 
iron with or without anemia, is estimated to affect more than two billion people around the world. Iron 
deficiency anemia is the most prevalent anemia (see figure 1) worldwide roughly affecting 1 of 8 persons, with 
the highest prevalence in developing countries. Still iron deficiency anemia often remains undiagnosed and 
untreated (Kassebaum, Jasrasaria & Naghavi, 2014). 
 
Figure (1): Normal and Anemia affected blood 
Iron (see figure 2) is tightly regulated at both the cellular and systemic level. Systemic iron homeostasis is 
under the control of hepcidin and is dominated by the erythropoietic needs for hemoglobin synthesis in the blood 
(Hentze, Muckenthaler, Galy & Camaschella, 2010).  
Thus, individuals at increased risk of developing iron deficiency are young children and adolescents, 
because of expanding erythropoiesis during rapid growth, and postpartum women. Also regular blood donors 
may develop iron deficiency and anemia after multiple donations (Cable, Glynn & Kiss, 2011).  
Insufficient iron intake, diets containing poorly bioavailable sources of iron, and parasitic infections account 
for most cases in low-income countries. In high-income countries, iron deficiency anemia, usually with the 
exception of groups with increased iron needs, may point to pathologic conditions associated with poor iron 
absorption and/or chronic blood loss. 
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Figure (2): Normal, Anemia and Polycythemia blood 
Global burden disease studies point out that one of the top cause-specific anemias is iron deficiency (ID). 
Recent advances in knowledge of iron homeostasis have shown that fragile patients are a new target population 
in which the correction of ID might impact their morbidity, mortality and quality of life (De Franceschi, Iolascon, 
Taher & Cappellini, 2017).  
Iron is necessary not only in the haem of haemoglobin for oxygen transport (see figure 3), but also as a 
cofactor for several enzymes. For example, iron ions play central roles in the mitochondrial respiratory chain and 
in tissue oxygen storage in myoglobin (Haas & BrownlieIron, 2001).  
Therefore, iron is necessary in cells that require sustained adenosine triphosphate synthesis, such as skeletal 
myocytes and cardiomyocytes, in addition to cells of the erythropoietic lineage (Cairo, Bernuzzi & Recalcati, 
2006). 
 
Figure (3): Haemoglobin for oxygen transport 
In many cases, ID diagnosis appears simple with a low ferritin level. However, in some patients the 
diagnosis can be difficult between ID anaemia and anaemia of chronic diseases; therefore other specific 
indicators of ID are warranted. In recent years, new parameters have been developed to help physicians in the 
diagnosis of ID in complex clinical settings (Polin, Coriat, Perkins, Dhooge, Abitbol, Leblanc & Chaussade, 
2013). 
The underlying cause of ID must be sought, to achieve an etiological treatment and to identify a potentially 
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serious diagnosis. In premenopausal women, iron deficiency anaemia is generally attributed to menstrual blood 
loss. Other aetiologies for ID are mainly gastrointestinal: digestive blood loss or iron malabsorption. ID warrants 
extensive investigations of the gastrointestinal tract including upper gastrointestinal endoscopy and colonoscopy 
since the probability of malignant tumours or ulcers, as the cause of excessive blood loss, is relatively high. If 
upper gastrointestinal endoscopy and colonoscopy are negative, further direct visualization of the small bowel is 
indicated in most situations. Recent advances have been made in the development of tools to examine the small 
bowel.  
Treatment of ID anemia involves identifying and treating the cause of the condition, as well as replacing 
iron. Several methods of iron supplementation are currently available in oral or parenteral administration. In this 
review, we herein present recent advances in the understanding of ID, aetiological diagnosis and treatment 
 
1.2 Problem Statement 
Iron deficiency is the most frequent cause of anaemia worldwide. It impairs quality of life, increases asthenia and 
can lead to clinical worsening of patients. In addition, iron deficiency has a complex mechanism whose 
pathologic pathway is recently becoming better understood. The discovery of hepcidin has allowed a better 
clarification of iron metabolism regulation. Furthermore, the ratio of concentration of soluble transferrin receptor 
to the log of the ferritin level, has been developed as a tool to detect iron deficiency in most situations. Therefore, 
the problem of this research lies in exploring the cause of iron deficiency that always be sought because the 
underlying condition can be serious. This review will summarize the current knowledge regarding diagnostic 
algorithms for iron deficiency anemia. The majority of aetiologies occur in the digestive tract, and justify 
morphological examination of the gut. First line investigations are upper gastrointestinal endoscopy and 
colonoscopy, and when negative, the small bowel should be explored; newer tools such as video capsule 
endoscopy have also been developed. The treatment of iron deficiency is aetiological if possible and iron 
supplementation whether in oral or in parenteral form.  
 
1.3 Terminology 
1.3.1 Anemia 
The World Health Organization defines anemia as a haemoglobin (Hb) concentration below 13 g/dl in men over 
15 years of age, below 12 g/dl in non-pregnant women over 15 years of age, and below 11 g/dl in pregnant 
women (World Health Organisation, 2008). 
The diagnostic criteria for anaemia in IDA vary between published studies. The normal range for Hb also 
varies between different populations in the world. Therefore it is reasonable to use the lower limit of the normal 
range for the laboratory performing the test to define anemia (Goddard, James, McIntyre & Scott, 2011). 
1.3.2 Iron deficiency 
Modern automated cell counters provide measurements of the changes in red cells that accompany iron 
deficiency: reduced mean cell Hb (MCH) hypochromiadand increased percentage of hypochromic red cells and 
reduced mean cell volume (MCV) microcytosis (Lewis, Bain, Bates, Dacie & Lewis, 2001).  
The MCH is probably the more reliable because it is less influenced by the counting machine used and by 
storage. Both microcytosis and hypochromia are sensitive indicators of iron deficiency in the absence of chronic 
disease or coexistent vitamin B12 or folate deficiency (Jolobe, 2000). 
1.3.3 Functional iron deficiency 
Functional iron deficiency’ occurs where there is an inadequate iron supply to the bone marrow in the presence 
of storage iron in cells of the monocyte macrophage system. Perhaps the most important clinical setting for this 
is in patients with renal failure who require parenteral iron therapy to respond to administered erythropoietin to 
correct anaemia. Functional iron deficiency also occurs in many chronic inflammatory diseases (eg, rheumatoid 
arthritis and inflammatory bowel disease) the anemia of chronic disease. 
 
1.4 Iron metabolism and its regulation: physiology and pathology 
1.4.1 Iron metabolism 
Iron in the diet exists in ferrous or ferric form. Ferrous iron (Fe2+) can cross the apical brush border of 
enterocytes through the ferrous iron (Fe2+) transporter Divalent Metal ion Transporter 1 (DMT1). Ferric iron, 
that is the most important iron in diet, needs to be reduced in ferrous iron with the action of the iron reductase 
before absorption. The newly absorbed iron (1–2 mg per day) enters the intracellular iron pool of enterocyte. If 
the body does not require the iron, it is loaded onto the iron storage protein ferritin. Iron required by the body is 
transferred across the basolateral membrane of enterocyte by ferroportin (FPN) (Anderson, Frazer & McLaren, 
2009).  
Hephaestin (or Ceruleoplasmin) converts ferric iron to ferrous iron, which can be bound to transferrin and 
transported in the plasma. The major source of iron is provided by the macrophages that recycle iron from 
senescent red blood cells. Iron bound to transferrin enters in the hepatocytes by endocytose of the transferrin–
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transferrin receptor complex. Iron loss is from desquamation, menstruation and other blood loss (1–2 mg per day) 
(Zhu, Kaneshiro & Kaunitz, 2010). 
 
Figure (4): Iron metabolism 
1.4.2 Homeostasis of iron metabolism 
Hepcidin, a protein first described 10 years ago by Nicolas et al., is an iron regulatory hormone, which plays the 
role of sensor for the body’s iron demands. This polypeptide is produced by the hepatocyte. The binding of 
hepcidin to ferroportin leads to the endocytosis and degradation of ferroportin. The direct consequence of this 
phenomenon is the decreasing of iron transfer into the blood plasma from the enterocytes, macrophages and iron-
storing hepatocytes. The production of hepcidin is influenced by iron plasmatic concentration, erythropoietic 
requirements for iron and inflammation in chronic diseases. In ID and in haemorrhagic or haemolytic anaemia, 
the production of hepcidin in hepatocytes decreases and both iron absorption in the duodenum and the release of 
iron from stores are greatly increased. In anaemia of chronic disease, hepcidin is over expressed by the action of 
cytokines such as IL6. The direct consequences of this inflammation are the iron sequestration in hepatocytes 
and macrophages and the decreasing of intestinal iron absorption. These disorders result in a “functional” ID 
since iron store is not available for the needs of the body, mostly erythropoiesis (Ganz, 2011). 
1.4.3 Anemia in iron deficiency 
Erythropoiesis in physiological conditions consumes 25 mg of iron daily. Iron from the circulation is transported 
by plasma transferrin and delivered to the erythroblast via the transferrin receptor. Iron is essential for the 
synthesis of the haemoglobin molecule (one molecule of haemoglobin contains four iron atoms). ID leads to a 
reduction of the synthesis of haemoglobin molecule. The direct consequence is the increasing number of mitoses 
of erythroblasts leading to microcytosis and hypochromia (Jolobe, 2000). 
 
1.5 Mechanism of adaptation to iron deficiency 
Iron deficiency anemia usually develops slowly. As iron levels decline in the stores (iron deficiency) and in the 
circulation (iron restricted erythropoiesis) becoming insufficient for the full hemoglobinization of mature 
erythroblasts (iron deficiency anemia), the liver peptide hormone hepcidin is transcriptionally suppressed.4 
Indeed serum hepcidin levels are significantly lower in young women with a negative iron balance compared 
with males and postmenopausal women, and are even undetectable in serum of individuals with iron deficiency 
anemia. The decrease of hepcidin enhances iron release into plasma through ferroportin from both enterocytes 
and macrophages in the attempt of maintaining normal transferrin (Galesloot, Vermeulen & Geurts-Moespot, 
2011). 
 
1.6 Traditional and emerging causes of iron deficiency 
Groups of individuals at risk and traditional causes of iron deficiency and iron deficiency anemia are well known, 
summarized in table (1) and will not be extensively discussed here. For thorough coverage the readers are 
referred to a recent review (Kassebaum, Jasrasaria & Naghavi, 2014). 
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Table (1): Causes of iron deficiency anemia 
Digestive disorders 
Increased losses of iron 
Cancer/polyp: colon, stomach, esophagus, small bowel 
Peptic ulcer, esophagitis 
NSAID use 
Inflammatory bowel disease: ulcerative colitis, Crohn's disease 
Intestinal parasites 
Vascular lesions: angiodysplasia, watermelon stomach 
Meckel’s diverticulum 
Reduced iron absorption 
Celiac disease 
Bacterial overgrowth 
Whipple’s disease 
Lymphangiectasia 
Gastrectomy (partial and total) and gastric atrophy 
Gut resection or bypass 
Urological and gynecological disorders 
Intravascular hemolysis 
Deficient iron intake 
Reduced iron absorption is the second category of ID causes of digestive origin, and can be caused by celiac 
disease, atrophic gastritis, and postsurgical status (gastrectomy, intestinal resection) among others. Celiac disease 
is very relevant and specific evaluation to exclude it must be performed. In a study on patients referred to a 
specialized gastroenterological consultation because of ID or IDA, celiac disease was finally the diagnosis in 
10% of cases; other authors described that at least 2%-3% of patients with IDA are finally diagnosed as celiac 
disease (Yates, Logan & Stewart, 2004). 
Impaired iron absorption may result from surgical and medical conditions. Bariatric surgery, increasingly 
performed to control caloric intake or diabetes, is emerging as a potential cause of iron deficiency. Post-
operative iron deficiency is influenced by preoperative iron status, which is often low in obese patients, and is 
found more commonly in females (Khanbhai, Dubb, Patel, Ahmed & Richards, 2015). 
 
1.7 Laboratory diagnosis of iron deficiency anemia 
The World Health Organization defines anemia as blood hemoglobin values of less than 7.7 mmol/l (13 g/dl) in 
men and 7.4 mmol/l (12 g/dl) in women. Typically, the evaluation of the cause of anemia includes a complete 
blood cell count, peripheral smear, reticulocyte count, and serum iron indices. The severity of anemia is based on 
the patient’s hemoglobin/hematocrit level. Iron deficiency anemia is characterized by microcytic, hypochromic 
erythrocytes and low iron stores. The mean corpuscular volume is the measure of the average red blood cell 
volume and mean corpuscular hemoglobin concentration is the measure of the concentration of hemoglobin in a 
given volume of packed red blood cells. The normal reference ranges for mean corpuscular volume is 80–100 fL 
and mean corpuscular hemoglobin concentration is 320–360 g/l. The patient’s cells are said to be microcytic and 
hypochromic, respectively, when these values are less than the normal reference range. Of note, up to 40% of 
patients with true iron deficiency anemia will have normocytic erthrocytes (i.e. a normal mean corpuscular 
volume does not rule out iron deficiency anemia) (Bermejo & Garcia-Lopez, 2009).  
The red cell distribution width is a measure of the variation of red blood cell width and is used in 
combination with the mean corpuscular volume to distinguish an anemia of mixed cause from that of a single 
cause. The normal reference range is 11–14%; an elevated red cell distribution width value signifies a variation 
in red cell size, which is known as anisocytosis. The red cell distribution width may be elevated in the early 
stages of iron deficiency anemia or when a patient has both iron deficiency anemia and folate with or without 
vitamin B12 deficiencies, which both produce macrocytic anemia. It is not uncommon for the platelet count to be 
greater than 450,000/µl in the presence of iron deficiency anemia. Upon examination of a patient’s peripheral 
smear with chronic iron deficiency anemia one will typically see hypochromic, microcytic erythrocytes; 
thrombocytosis may also be apparent. It is important to note that microcytosis visible on the peripheral smear 
may be seen prior to abnormalities on the complete blood cell count. If the patient has coexistent folate or 
vitamin B12 deficiency, the peripheral smear will be a mixture of macrocytic and microcytic hypochromic 
erythrocytes, along with normalization of the mean corpuscular volume. 
In the presence of an underlying infection or inflammation other iron markers may be useful including the 
reticulocyte hemoglobin content which, because reticulocytes are only 1–2 days old, is reflective of the iron 
available in the bone marrow for erythropoiesis. The alternative, which is likely to be more readily available, is 
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the measurement of soluble transferrin receptor. In the setting of iron deficiency with increased erythroid activity 
(e.g. following administration of exogenous erythropoiesis stimulating agents), there is increased expression of 
membrane transferrin receptors in the bone marrow and some of these receptors are detectable in the serum. The 
limitations are that it is not as reliable as ferritin, it is not yet widely available, and the clinician must exclude 
other causes of elevated erythroid activity (Wish, 2006). 
 
1.8 Oral iron therapy and its limitations 
Traditionally hemodynamically stable patients with iron deficiency anemia resultant from chronic blood loss 
from the gut are prescribed oral iron therapy. The two categories of iron supplements are those containing the 
ferrous form of iron and those containing the ferric form of iron. The most widely used iron supplements are 
those that contain the ferrous form of iron given that it is the better absorbed of the two. The three commonly 
administered types of ferrous iron supplements: ferrous fumarate, ferrous sulfate, and ferrous gluconate, which 
differ in the amount of elemental iron (the form of iron in the supplement that is available for absorption by the 
body), and contain 33%, 20%, and 12% iron, respectively (NIH, 2010). Recent studies have suggested that these 
iron preparations are essentially equivalent in terms of bioavailability (Harrington et al. 2011). 
The recommended daily dose of treatment by the Centers for Disease Control and Prevention (CDC) ranges 
from 150 mg/day to 180 mg/day of elemental iron administered in divided doses two to three times a day [CDC, 
1998]. The reticulocyte count begins to increase within the first week of iron therapy, whereas the hemoglobin 
usually trails by 1–2 weeks (National Institutes of Health, 2010).  
Oral iron supplements are desirable as first-line therapy as they are safe, cheap, and effective in restoring 
iron balance in the average chronic gastrointestinal bleeder. 
Therapy with iron supplements may be limited by gastrointestinal side effects, such as abdominal 
discomfort, nausea, vomiting, constipation, and dark colored stools. Enteric-coated and delayed-release iron 
supplements have been developed to increase compliance as they are associated with fewer side effects; however, 
they are not as well absorbed as the no enteric-coated preparations. 
Physicians are often faced with the challenge of managing iron deficiency anemia with oral iron when a 
patient’s iron losses exceed the maximum amount of iron that the gut is able to absorb. It is this group of patients 
that generally requires repeated transfusions and suffers end-organ damage as the patients are not able to 
replenish their iron stores with oral supplementation alone. One of the most challenging groups of patients is 
those patients that suffer from chronic gastrointestinal bleeding secondary to vascular angiodysplasia. These 
patients typically have multiple lesions that occur in clusters and/or scattered throughout the gastrointestinal tract, 
and frequently rebleed resulting in chronic iron deficiency anemia. When the patient’s gastrointestinal blood loss 
results in more iron loss than that which they are able to absorb from the gut, these patients develop anemia that 
is clinically refractory to oral iron therapy.  
 
1.9 Intravenous iron therapy and its limitations 
Intravenously administered iron is one approach to replacing iron losses in patients with chronic gastrointestinal 
bleeding in which blood loss exceeds 10 ml/day (around 5 mg iron). With the use of intravenous iron the desired 
serum iron levels, in which the marrow production can increase by fourfold to eightfold, can be achieved.  
Hillman and Henderson previously showed that the maximum iron delivery from reticuloendothelial iron 
stores is 40–60 mg of iron/day to the bone marrow for erythropoiesis. Supplementation with oral iron provides 
60–80 mg iron/day, whereas intravenous iron or nonviable red cells provide 80–160 mg iron/day. They found 
that the maximum red blood cell production achieved by patients with a mean serum iron less than 70 µg/100 ml 
was between 2.5 and 3.5 times normal. With oral iron supplementation, patients were able to achieve serum iron 
values between 70 µg/100 ml and 150 µg/100 ml, and red blood cell production was able to increase to four to 
five times normal. Only when nonviable red cells or intravenous iron dextran was administered was the iron 
supply sufficient to increase the serum iron to values greater than 200 µg/100 ml with a concomitant increase in 
marrow production to 4.5–7.8 times normal (Figure 5).  
 
Figure (5): Response of the bone marrow in relation to the level of serum iron 
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It is important to note that this response was transient lasting only 7–10 days as the excess iron was 
subsequently sequestered in the reticuloendothelial system. The physician can estimate a patient’s total iron 
deficit and then decide how much to administer intravenously. 
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